5718-83-2

Basic information

• Product Name: Rhodanine-3-acetic acid
• Synonyms: 3-Thiazolidineacetic acid;Rhodanine acetic acid;Rhodanine-3-ethanoic acid;2-Thioxo-4-oxothiazolidine-3-acetic acid;Rhodanine-N-acetic acid,98%;RHODANINE-N-ACETIC ACID FOR SYNTHESIS;2-(4-Oxo-2-thioxothiazolidin-3-yl)acetic acid;TIMTEC-BB SBB003632
• CAS NO: 5718-83-2
• Molecular Formula: C₅H₅NO₃S₂
• Molecular Weight: 191.23
• EINECS: 227-220-1
• Product Categories: INTERMEDIATES;Heterocycles;Acetics acid and esters
• Mol File: 5718-83-2.mol
• Article Data: 30

Chemical Properties

• Melting Point: 145-148 °C(lit.)
• Boiling Point: 375.4 °C at 760 mmHg
• Flash Point: 180.8 °C
• Appearance: /solid
• Density: 1.492 (estimate)
• Vapor Pressure: 1.14E-06mmHg at 25°C
• Refractive Index: 1.5480 (estimate)
• Storage Temp.: Store below +30°C.
• Solubility: methanol: soluble25mg/mL, clear, yellow
• PKA: 3.75±0.10(Predicted)
• BRN: 149513
• CAS DataBase Reference: Rhodanine-3-acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: Rhodanine-3-acetic acid(5718-83-2)
• EPA Substance Registry System: Rhodanine-3-acetic acid(5718-83-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-41
• Safety Statements: 26-36-39-25
• WGK Germany: 3
• F: 10-23
• TSCA: Yes
• Hazardous Substances Data: 5718-83-2(Hazardous Substances Data)

Usage

Chemical Properties

PALE YELLOW FINE CRYSTALINE POWDER

Uses

3-Rhodanineacetic Acid is an inhibitor for copper corrosion in acidic media.

InChI:InChI=1/C5H5NO3S2/c7-3-2-11-5(10)6(3)1-4(8)9/h1-2H2,(H,8,9)/p-1

Upstream product

• 2365-48-2 Methyl thioglycolate 
• 4385-41-5 isothiocyanato-acetic acid 
• 6326-83-6 bis(carboxymethyl)trithiocarbonate 
• 56-40-6 glycine 
• 75-15-0 carbon disulfide 
• 7748-25-6 potassium chloroacetate 
• 141-84-4 2-thioxo-4-thiazolidinone 
• 79-11-8 chloroacetic acid 
• 29677-65-4 N-carboxymethylsulfanylthiocarbonyl-glycine 
• 623-51-8 ethyl 2-sulfanylacetate 
• 3926-62-3 sodium monochloroacetic acid 
• 39680-96-1 C₃H₅NO₂S₂*H₃N 
• 6861-95-6 N-dithiocarboxy-glycine ; ammonium salt 
• 149789-77-5 methyl (4-oxo-2-thioxo-1,3-thiazolidine-3-yl)acetate 

Downstream Products

• 82158-77-8 (5-trans-cinnamyliden-4-oxo-2-thioxo-thiazolidin-3-yl)-acetic acid 
• 25651-76-7 {5-[1-methyl-2-(3-methyl-thiazolidin-2-yliden)-ethyliden]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid 
• 76971-10-3 {5-[(1-ethyl-1H-[2]quinolyliden)-ethyliden]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid 
• 25962-03-2 {5-[2-(3-ethyl-3H-benzothiazol-2-ylidene)-ethylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid 
• 82158-61-0 3-Carboxymethyl-5--rhodanin 
• 82158-60-9 3-Carboxymethyl-5--rhodanin 
• 92423-68-2 3-Carboxymethyl-5-(5-brom-indolyl-(3)-methylen)-rhodanin 
• 1022-55-5 3-Carboxymethyl-5-(3'-isoxazolylmethylen)-rhodanin 
• 130786-47-9 {5-[4-Chloro-but-(Z)-ylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid 
• 101004-65-3 {5-[1-{4-[(2-Chloro-ethyl)-methyl-amino]-phenyl}-meth-(Z)-ylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid 
• 125261-87-2 ammonium 5-<4-(2-acetamido-2-deoxy-β-D-glucopyranosyloxy)-3-methoxymethylene>-2-thioxothiazolidin-4-one-3-acetate 
• 82159-06-6 [(5Z)-(5-benzylidene-4-oxo-2-thioxo-1,3-thiazolidin-3-yl)]acetic acid 
• 101004-60-8 3-(Carboxymethyl)-5-rhodanine 
• 136401-73-5 5-<4-<2-(6-Methyl-2-pyridyl)ethoxy>benzylidene>rhodanine-3-acetic Acid 

Relevant articles and documents

Design and synthesis of amino acid derivatives of substituted benzimidazoles and pyrazoles as Sirt1 inhibitors

Owing to its presence in several biological processes, Sirt1 acts as a potential therapeutic target for many diseases. Here, we report the structure-based designing and synthesis of two distinct series of novel Sirt1 inhibitors, benzimidazole mono-peptide

Pyrimidine-thiazolidinone derivatives

Pyrimidine-thiazolidinone derivatives may be used for preventing or treating diseases in humans or animals, and have demonstrated efficacy specifically in treating type-2 diabetes. Methods of synthesizing the pyrimidine-thiazolidinone derivatives, described herein, can provide high yields in a short time and with high purity. The pyrimidine-thiazolidinone derivatives demonstrate improved hypoglycemic activity compared to most anti-diabetic drugs currently available.

Design and synthesis of biaryloxazolidinone derivatives containing a rhodanine or thiohydantoin moiety as novel antibacterial agents against Gram-positive bacteria

Novel biaryloxazolidinone derivatives containing a rhodanine or thiohydantoin moiety were designed, synthesized and evaluated for their antibacterial activity. The key compounds 7 and 9 were synthesized by the knoevenagel condensation of intermediate aldehyde 5 with rhodanine derivatives 6a?6b. The preliminary study showed that compounds 7, 9 and 10e exhibited potent antibacterial activity with MIC values of 0.125 μg/mL against S. aureus, MRSA, MSSA, LREF and VRE pathogens, using linezolid and radezolid as the positive controls. The most promising compound 10e exhibited potent antibacterial activity against tested clinical isolates of MRSA, MSSA, VRE and LREF with MIC values in the range of 0.125–0.5 μg/mL, and the potency of 10e against clinical isolates of LREF was 64-fold higher than that of linezolid. Moreover, compound 10e was non-cytotoxic with an IC50 value of 91.04 μM against HepG2 cell. Together, compound 10e might serve as a novel antibacterial agent for further investigation.